Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

DREAM raises pain relief hopes

15.01.2002


No dream: these mice feel little pain.
J. Penniger


Missing protein leaves mice impervious to pain

Researchers have a new lead for treating pain. A protein called DREAM appears to play a key role in how mice respond to heat, touch and inflammation1.

Mice lacking DREAM seem oblivious to all types of pain, find Josef Penninger and his colleagues at The AMGEN Institute, Toronto, Canada. The animals can bear acute pain - the kind caused for example by heat, pressure, or injections as well as chronic inflammatory pain - that which arthritis patients suffer. They seem otherwise normal.



DREAM was first identified in 1999, when it was known by three different names and had three different proposed functions in biological systems. "It was very unpredictable what DREAM would be doing physiologically," says Penninger.

The protein’s full name is Downstream Regulatory Element Antagonistic Modulator. Low DREAM levels are accompanied by high levels of dynorphin in the mice’s spinal cords. This morphine-like substance is believed to alleviate the animals experience of pain. "It’s exciting because it looks to be so specific," says Penninger.

While the results suggest altering DREAM function might be a way to change pain perception, practical applications are a long way off. "This is a major mechanistic insight," says John Wood who studies pain receptors at University College in London - but whether or not DREAM acts in a similar way in humans remains to be seen, he cautions.

Current estimates suggest that one in five people worldwide live with chronic pain from cancer and other debilitating diseases. Treatments with fewer side effects than existing analgesics have long been a goal for researchers.

References

  1. Cheng, H.-Y. M. et al. DREAM is a critical transcriptional repressor for pain modulation. Cell, 108, 31 - 43, (2002).


VIRGINIA GEWIN | © Nature News Service
Further information:
http://www.nature.com/nsu/020114/020114-1.html

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>